Show simple item record

Long-term Safety of Rivastigmine in Parkinson Disease Dementia: An Open-Label, Randomized Study

dc.contributor.authorvan Laar, Teus
dc.contributor.authorBurn, David
dc.contributor.authorMicheli, Federico
dc.contributor.authorStorch, Alexander
dc.contributor.authorEmre, Murat
dc.contributor.authorPoewe, Werner
dc.contributor.authorDe Deyn, Peter Paul
dc.contributor.authorBarone, Paolo
dc.contributor.authorKulisevsky, Jaime
dc.contributor.authorPourcher, Emmanuelle
dc.contributor.authorStrohmaier, Christine
dc.contributor.authorTenenbaum, Nadia
dc.contributor.authorCallegari, Francesca
dc.contributor.authorPahwa, Rajesh
dc.contributor.authorDurif, Frank
dc.date.accessioned2021-03-05T09:37:28Z
dc.date.available2021-03-05T09:37:28Z
dc.date.issued2014
dc.identifier.citationEmre M., Poewe W., De Deyn P. P. , Barone P., Kulisevsky J., Pourcher E., van Laar T., Storch A., Micheli F., Burn D., et al., "Long-term Safety of Rivastigmine in Parkinson Disease Dementia: An Open-Label, Randomized Study", CLINICAL NEUROPHARMACOLOGY, cilt.37, ss.9-16, 2014
dc.identifier.issn0362-5664
dc.identifier.othervv_1032021
dc.identifier.otherav_9eb6b6c1-d86b-4ac1-a1f9-5452c104fd60
dc.identifier.urihttp://hdl.handle.net/20.500.12627/106582
dc.identifier.urihttps://doi.org/10.1097/wnf.0000000000000010
dc.description.abstractObjective: This study investigated the long-term safety of rivastigmine (12 mg/d capsules, 9.5 mg/24 h patch) and effects on motor symptoms in patients with mild-to-moderately severe Parkinson disease dementia.
dc.language.isoeng
dc.subjectNöroloji
dc.subjectEczacılık
dc.subjectTemel Eczacılık Bilimleri
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectDahili Tıp Bilimleri
dc.subjectKLİNİK NEUROLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.titleLong-term Safety of Rivastigmine in Parkinson Disease Dementia: An Open-Label, Randomized Study
dc.typeMakale
dc.relation.journalCLINICAL NEUROPHARMACOLOGY
dc.contributor.departmentMedical University of Innsbruck , ,
dc.identifier.volume37
dc.identifier.issue1
dc.identifier.startpage9
dc.identifier.endpage16
dc.contributor.firstauthorID213026


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record